JPRN-UMIN000046634尚未招募未知
Resection of initially unresectable hepatocellular carcinoma with atezolizumab plus bevacizumab Additional study: Identification of biomarkers for predicting therapeutic effects and adverse events - RACB additional study
ational Center for Global Health and Medicine0 个研究点目标入组 50 人开始时间: 2022年1月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Currently receiving oral or parenteral anticoagulants or thrombolytics within 10 days prior to enrollment. 2. Have untreated or not adequately treated esophageal varices at high risk of bleeding, or a history of bleeding due to esophageal varices within 180 days prior to enrollment. 3. Had thrombosis and/or embolism within 180 days before enrollment. 4. Has undergone major surgical procedures within 28 days before enrollment. 5. Has received systemic immunostimulatory agents within 180 days prior to enrollment. 6. Has received systemic immunosuppressants within 14 days before enrollment. 7.History and complications of autoimmune disease within 180 days prior to enrollment 8. History of active double cancer or malignancy. 9. Currently participating in another study of unapproved drugs or a study requiring intervention. 10.Critical cardiovascular disease, unstable arrhythmia or unstable angina in the 90 days prior to enrollment. 11.Pregnant, breastfeeding, positive in pregnancy test, women and men unwilling to contraceptive during the study period. 12. Has clinically uncontrolled pleural effusion, pericardial effusion or ascites. 13. Has complications of hepatic encephalopathy 14. Uncontrollable hypertension, severe infection, hemodialysis 15. Has a history of serious allergic or anaphylactic reactions to chimeric antibody, humanized antibody, or fusion protein. 16.Hypersensitivity to either Chinese hamster ovary cell-derived products or components of atezolizumab or bevacizumab products. 17.Has a history of hemorrhagic disease, gastrointestinal hemorrhage or active hemoptysis. 18. Difficult to ingest medication 19.HIV-positive 20. Active pulmonary fibrosis or interstitial pneumonia 21.Has received blood transfusions or G-CSF products within 14 days prior to enrollment 22. The attending physician judges that the patient is not suitable for participating in the study.
研究者
相似试验
招募中
不适用
RACB StudyHepatocellular CarcinomaJPRN-jRCTs051210148Hatano Etsuro50
已完成
不适用
Radial incision and cutting for refractory hepaticojejunostomy anastomotic stricturesHepaticojejunostomy anastomotic stricturesJPRN-UMIN000034057Aichi Medical University10
进行中（未招募）
不适用
Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001)Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Rap-001) - treatment of HCC with rapamyciAdvanced hepatocellular carcinoma (HCC)EUCTR2004-002834-20-ATniversitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie30
招募中
不适用
Irresectable intrahepatic cholangiocellular carcinoma:Evaluation of the Efficacy of multimodal treatment by interstitial HDR-Brachytherapy combined with Gemcitabine/Cisplatin ChemotherapyC22.1Intrahepatic bile duct carcinomaDRKS00007161niversitätsklinikum Magdeburg50
已完成
不适用
Preoperative arterial embolization of hepatocellular carcinoma using DC beads; embolization and resect studyhepatocellular carcinomaJPRN-UMIN000014607Okayama University Hospital6